Adverse effects of HAIC-FOLFOX-B or HAIC-FOLFIRI-B.
收藏NIAID Data Ecosystem2026-05-10 收录
数据链接：
官方服务：
资源简介：
Adverse effects of HAIC-FOLFOX-B or HAIC-FOLFIRI-B.
应用场景：
创建时间：
2025-11-06
相关数据集
Supplementary Material for: Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas
Background: Carboplatin-etoposide (CarboEtop) is a 1st-line option for patients with advanced extra-pulmonary (EP), poorly-differentiated (PD) neuroendocrine carcinoma (NEC). Different schedules are u
NIAID Data Ecosystem30
Effectiveness of purely tightened-schedule dose-dense regimens in neo-adjuvant and adjuvant chemotherapies for early breast cancer: a systematic review and meta-analysis
Effectiveness of purely tightened-schedule dose-dense regimens in neo-adjuvant and adjuvant chemotherapies for early breast cancer: a systematic review and meta-analysis
DataONE2019-02-08 更新30
Additional file 2 of Clinical and therapeutic features and prognostic factors of metastatic colorectal cancer over age 80: a retrospective study
Additional file 2: Table S1: Summary of the chemotherapy regimens. Chemotherapy regimens received by patients in the first-, second-, and third-line treatments separated according to those aged
Figshare2021-07-21 更新20
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
This study is designed to compare the efficacy and safety of two-weekly RAILIRI regimen with FOLFIRI regimen in the treatment of advanced colorectal cancer patients in the second-line setting.
NIAID Data Ecosystem30
S-1 and CPT-11 plus ramucirumab (IRIS+Rmab) as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: A multicenter phase II study in Japan (N-DOCC-F-C-1701)
Interventions: Treatment by IRIS+Rmab Ramucirumab at a dose of 10mg/kg was administered as a 120-min infusion and irinotecan at a dose of 150mg/m2 by adjustment by UGT1A1 was administered as a 90-min
NIAID Data Ecosystem30
